JP2010516786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516786A5 JP2010516786A5 JP2009547455A JP2009547455A JP2010516786A5 JP 2010516786 A5 JP2010516786 A5 JP 2010516786A5 JP 2009547455 A JP2009547455 A JP 2009547455A JP 2009547455 A JP2009547455 A JP 2009547455A JP 2010516786 A5 JP2010516786 A5 JP 2010516786A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer cell
- exosome
- immunosuppressive polypeptides
- superantigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims 55
- 210000001808 Exosomes Anatomy 0.000 claims 22
- 230000001506 immunosuppresive Effects 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000038129 antigens Human genes 0.000 claims 9
- 108091007172 antigens Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 101710044433 SAG Proteins 0.000 claims 6
- 231100000617 Superantigen Toxicity 0.000 claims 6
- 229920000023 polynucleotide Polymers 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 231100000655 Enterotoxin Toxicity 0.000 claims 4
- 231100000776 Exotoxin Toxicity 0.000 claims 4
- 239000002095 exotoxin Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 101710012053 CD274 Proteins 0.000 claims 2
- 102100007290 CD274 Human genes 0.000 claims 2
- 102100019456 CD276 Human genes 0.000 claims 2
- 101700015421 CD276 Proteins 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 2
- 101700052761 MUC1 Proteins 0.000 claims 2
- 102100006037 MUC1 Human genes 0.000 claims 2
- 101710011976 PDCD1LG2 Proteins 0.000 claims 2
- 102100007289 PDCD1LG2 Human genes 0.000 claims 2
- -1 SSX-1 Proteins 0.000 claims 2
- 108020004459 Small Interfering RNA Proteins 0.000 claims 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 229940076156 Streptococcus pyogenes Drugs 0.000 claims 2
- 206010044250 Toxic shock syndrome staphylococcal Diseases 0.000 claims 2
- 231100000765 Toxin Toxicity 0.000 claims 2
- 210000004748 cultured cells Anatomy 0.000 claims 2
- 230000002297 mitogenic Effects 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 102100006669 ALPP Human genes 0.000 claims 1
- 101710016999 ALPP Proteins 0.000 claims 1
- 102100007326 BIRC5 Human genes 0.000 claims 1
- 101700073164 CH63 Proteins 0.000 claims 1
- 101700076376 CKAP4 Proteins 0.000 claims 1
- 102100001891 CTAG1A Human genes 0.000 claims 1
- 101710004449 CTAG1A Proteins 0.000 claims 1
- 101710003743 CTDSP1 Proteins 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 101710027871 HOXA7 Proteins 0.000 claims 1
- 101710027953 HOXB7 Proteins 0.000 claims 1
- 101700017615 HSP82 Proteins 0.000 claims 1
- 101700042119 HSP83 Proteins 0.000 claims 1
- 101710023137 HSP90B1 Proteins 0.000 claims 1
- 101710006484 HSPA14 Proteins 0.000 claims 1
- 101710006403 HSPA5 Proteins 0.000 claims 1
- 102100015710 HSPA5 Human genes 0.000 claims 1
- 101700062887 HSPB1 Proteins 0.000 claims 1
- 102100017445 HSPB1 Human genes 0.000 claims 1
- 101700013735 HSPB3 Proteins 0.000 claims 1
- 101710013836 HSPD1 Proteins 0.000 claims 1
- 102100003681 HSPD1 Human genes 0.000 claims 1
- 101710022862 Hsp60A Proteins 0.000 claims 1
- 101710015344 LNPEP Proteins 0.000 claims 1
- 108050005300 MDM4 Proteins 0.000 claims 1
- 101710006465 MOD-E Proteins 0.000 claims 1
- 102100006044 MUC16 Human genes 0.000 claims 1
- 101700008449 MUC16 Proteins 0.000 claims 1
- 102100015262 MYC Human genes 0.000 claims 1
- 101700001465 NBR1 Proteins 0.000 claims 1
- 102100006167 NCL Human genes 0.000 claims 1
- 102100020079 NPM1 Human genes 0.000 claims 1
- 101710026364 NPM1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710022555 OPN1SW Proteins 0.000 claims 1
- 101710014166 PLAA Proteins 0.000 claims 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N PLAP Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 claims 1
- 102000001309 Proto-Oncogene Proteins c-mdm2 Human genes 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 108020004532 RAS Proteins 0.000 claims 1
- 101700044827 RNMT Proteins 0.000 claims 1
- 101700012849 SCP1 Proteins 0.000 claims 1
- 101710005494 SCPEP1 Proteins 0.000 claims 1
- 102100002942 SYCP1 Human genes 0.000 claims 1
- 101700084525 SYCP1 Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 101710026335 TP53 Proteins 0.000 claims 1
- 101710026354 TP63 Proteins 0.000 claims 1
- 108010091356 Tumor Protein p73 Proteins 0.000 claims 1
- 101700063261 UVRAG Proteins 0.000 claims 1
- 102100014952 VTCN1 Human genes 0.000 claims 1
- 101700068327 VTCN1 Proteins 0.000 claims 1
- 101710043893 cerB Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 101700057149 hsp60 Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 102000003735 mesothelin Human genes 0.000 claims 1
- 108090000015 mesothelin Proteins 0.000 claims 1
- 108010044762 nucleolin Proteins 0.000 claims 1
- 108010028067 procathepsin D Proteins 0.000 claims 1
- 108020001180 rasD Proteins 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
Claims (32)
- １又はそれより多い抗原を含んでなり、かつエキソソーム中に通常見出される１又はそれより多い免疫抑制性ポリペプチドを実質的に欠いている、細胞から単離したエキソソーム。
- 前記細胞が前記１又はそれより多い免疫抑制性ポリペプチドの発現を阻害するように改変されている請求項１に記載のエキソソーム。
- 前記細胞が前記１又はそれより多い免疫抑制性ポリペプチドの発現を特異的に抑制する１又はそれより多い阻害性ポリヌクレオチドを含んでなるように改変されている請求項２に記載のエキソソーム。
- 前記１又はそれより多い阻害性ポリヌクレオチドがsiRNAポリヌクレオチドを含んでなる請求項３に記載のエキソソーム。
- 前記細胞が培養細胞である請求項１〜４のいずれか１項に記載のエキソソーム。
- 前記細胞がガン細胞である請求項１〜５のいずれか１項に記載のエキソソーム。
- 前記ガン細胞が、卵巣ガン細胞、子宮頸ガン細胞、乳ガン細胞、子宮内膜ガン細胞、結腸ガン細胞、前立腺ガン細胞、肺ガン細胞、黒色腫細胞又は膵臓ガン細胞である請求項６に記載のエキソソーム。
- 前記細胞が、UL-1細胞、UL-2、UL-3細胞又はUL-6細胞である請求項６に記載のエキソソーム。
- 前記１又はそれより多い抗原が各々ガン細胞抗原を含んでなる請求項１〜８のいずれか１項に記載のエキソソーム。
- 前記ガン細胞抗原が、p53、p63、p73、mdm-2、プロカテプシン-Ｄ、B23、C23、PLAP、CA125、MUC-1、cerB/HER2、NY-ESO-1、SCP1、SSX-1、SSX-2、SSX-4、HSP27、HSP60、HSP90、GRP78、TAG72、HoxA7、HoxB7、EpCAM、ras、メソテリン、サービビン、EGFK、MUC-1及びc-mycからなる群より選択される請求項９に記載のエキソソーム。
- 前記１又はそれより多い免疫抑制性ポリペプチドが、FasL、プログラム死リガンド-１、プログラム死リガンド-２、B7-H3、B7-H4及びこれらの組合せからなる群より選択される
請求項１〜１０のいずれか１項に記載のエキソソーム。 - １又はそれより多い外因性抗原を含んでなる請求項１〜１１のいずれか１項に記載のエキソソーム。
- 前記１又はそれより多い外因性抗原がスーパー抗原を含んでなる請求項１２に記載のエキソソーム。
- 前記スーパー抗原がブドウ球菌エンテロトキシン(SE)、Streptococcus pyogenes外毒素(SPE)、Staphylococcus aureusトキシックショック症候群毒素(TSST-1)、レンサ球菌分裂誘発性外毒素(SME)又はレンサ球菌スーパー抗原(SSA)を含んでなる請求項１３に記載のエキソソーム。
- 請求項１〜１４のいずれか１項に記載のエキソソームを産生する細胞。
- (ａ)請求項１〜１４のいずれか１項に記載のエキソソーム；及び
(ｂ)医薬キャリア
を含んでなる組成物。 - (ａ)エキソソームを産生することができる細胞を用意し；
(ｂ)前記細胞による１又はそれより多い免疫抑制性ポリペプチドの発現を阻害し；そして
(ｃ)前記細胞により産生された、前記１又はそれより多い免疫抑制性ポリペプチドを実質的に欠いているエキソソームを単離すること
を含んでなる１又はそれより多い免疫抑制性ポリペプチドを実質的に欠いているエキソソームを製造する方法。 - 前記エキソソームを１又はそれより多い外因性抗原で修飾することを含んでなる請求項１７に記載の方法。
- 前記１又はそれより多い外因性抗原がスーパー抗原を含んでなる請求項１８に記載の方法。
- 前記スーパー抗原が、ブドウ球菌エンテロトキシン(SE)、Streptococcus pyogenes外毒素(SPE)、Staphylococcus aureusトキシックショック症候群毒素(TSST-1)、レンサ球菌分裂誘発性外毒素(SME)又はレンサ球菌スーパー抗原(SSA)を含んでなる請求項１９に記載の方法。
- 前記細胞が培養細胞である請求項１７〜２０のいずれか１項に記載の方法。
- 前記エキソソームの単離が、前記細胞を培養する培地を採集することを含んでなる請求項２１に記載の方法。
- 前記細胞がガン細胞である請求項１７〜２２のいずれか１項に記載の方法。
- 前記ガン細胞が、卵巣ガン細胞、子宮頸ガン細胞、乳ガン細胞、子宮内膜ガン細胞、結腸ガン細胞、前立腺ガン細胞、肺ガン細胞、黒色腫細胞又は膵臓ガン細胞である請求項２３に記載の方法。
- 前記細胞が、UL-1細胞、UL-2、UL-3細胞及びUL-6である請求項２４に記載の方法。
- 前記細胞による前記１又はそれより多い免疫抑制性ポリペプチドの発現抑制が、前記１又はそれより多い免疫抑制性ポリペプチドの発現を特異的に抑制する１又はそれより多い阻害性ポリヌクレオチドを前記細胞中に導入することを含んでなる請求項１７〜２５のいずれか１項に記載の方法。
- 前記１又はそれより多い阻害性ポリヌクレオチドがsiRNAポリヌクレオチドを含んでなる
請求項２６に記載の方法。 - 前記１又はそれより多い免疫抑制性ポリペプチドが、FasL、プログラム死リガンド-１、プログラム死リガンド-２、B7-H3、B7-H4及びこれらの組合せからなる群より選択される請求項１７〜２７のいずれか１項に記載の方法。
- ガンを治療するための請求項１６に記載の組成物。
- 前記ガンが充実性腫瘍である請求項２９に記載の組成物。
- 前記ガンが、卵巣ガン細胞、子宮頸ガン細胞、乳ガン細胞、子宮内膜ガン細胞、結腸ガン細胞、前立腺ガン細胞、肺ガン細胞、黒色腫細胞又は膵臓ガン細胞である請求項２９に記載の組成物。
- １又はそれより多い抗原に対して免疫応答を刺激するための請求項１６に記載の組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89764507P | 2007-01-26 | 2007-01-26 | |
| PCT/US2008/052205 WO2008092153A2 (en) | 2007-01-26 | 2008-01-28 | Modification of exosomal components for use as a vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516786A JP2010516786A (ja) | 2010-05-20 |
| JP2010516786A5 true JP2010516786A5 (ja) | 2011-03-17 |
Family
ID=39645226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547455A Pending JP2010516786A (ja) | 2007-01-26 | 2008-01-28 | ワクチンとしての使用のためのエキソソーム成分の改変 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8455188B2 (ja) |
| EP (1) | EP2117305A4 (ja) |
| JP (1) | JP2010516786A (ja) |
| CN (1) | CN101641010A (ja) |
| AU (1) | AU2008207735B2 (ja) |
| BR (1) | BRPI0806436A2 (ja) |
| CA (1) | CA2676143A1 (ja) |
| IL (1) | IL200027A0 (ja) |
| WO (1) | WO2008092153A2 (ja) |
| ZA (1) | ZA200905005B (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101600225B1 (ko) | 2005-06-08 | 2016-03-04 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| ES2736726T3 (es) * | 2006-03-09 | 2020-01-07 | Aethlon Medical Inc | Eliminación extracorpórea de partículas microvesiculares |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| IL282783B2 (en) * | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
| EP2806273B1 (en) | 2007-07-25 | 2017-09-06 | University of Louisville Research Foundation, Inc. | Exosome-associated microRNA as a diagnostic marker |
| EP3075864A1 (en) * | 2008-10-14 | 2016-10-05 | Caris MPI, Inc. | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
| CA2742324A1 (en) * | 2008-10-30 | 2010-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods for assessing rna patterns |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP3569254B1 (en) | 2009-04-17 | 2022-07-20 | Oxford University Innovation Limited | Composition for delivery of genetic material |
| ES2362589B1 (es) | 2009-12-28 | 2012-05-16 | Centre De Recerca En Salut Internacional De Barcelona | Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso. |
| US20120315324A1 (en) * | 2010-02-05 | 2012-12-13 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| BR112014002975A2 (pt) * | 2011-08-08 | 2017-03-01 | Caris Life Sciences Luxembourg Holdings S A R L | composições de biomarcador e métodos |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| WO2014049125A1 (en) * | 2012-09-28 | 2014-04-03 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) | Nucleotide sequence motifs directing nucleic acid location to extracellular vesicles |
| EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| JP6542197B2 (ja) * | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
| KR102541164B1 (ko) | 2014-01-21 | 2023-06-08 | 안자리움 바이오사이언시스 아게 | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 |
| FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
| AU2016219497A1 (en) * | 2015-02-09 | 2017-08-31 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors and PD-1 inhibitors for treating cancer |
| WO2018055080A1 (en) * | 2016-09-22 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
| WO2018085275A1 (en) * | 2016-11-02 | 2018-05-11 | The Regents Of The University Of California | Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy |
| KR102048228B1 (ko) * | 2016-12-02 | 2019-11-25 | 가톨릭대학교 산학협력단 | Ｔ 세포 자극용 엑소좀 및 이의 약제학적 용도 |
| WO2018173059A1 (en) | 2017-03-21 | 2018-09-27 | Exoprother Medical Ltd. | Native cell derived vesicles containing tumor suppressor proteins for therapy |
| US10815520B2 (en) | 2017-04-07 | 2020-10-27 | University Of Louisville Research Foundation, Inc. | Nanovesicles, methods, and systems for diagnosis and prognosis of cancer |
| CN107875376A (zh) * | 2017-10-18 | 2018-04-06 | 深圳先进技术研究院 | 包含ny‑eso‑1的微泡、其制备方法及用途 |
| CN115919798A (zh) * | 2022-11-14 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 基于肿瘤细胞外颗粒的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
| DE4210332C1 (ja) | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
| US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
| US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| JP3201610B2 (ja) | 1995-03-17 | 2001-08-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍を処置する方法 |
| US6203787B1 (en) | 1997-10-10 | 2001-03-20 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
| WO1997005900A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US6235280B1 (en) | 1996-04-12 | 2001-05-22 | Malaya Chatterjee | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| JP2001509135A (ja) | 1996-10-11 | 2001-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法 |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6180082B1 (en) | 1997-11-24 | 2001-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method to enhance tissue accumulation of radiolabeled compounds |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| FR2785543B1 (fr) | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| BR0012325A (pt) | 1999-07-09 | 2002-05-21 | American Home Prod | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
| US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
| EP1290161B1 (en) | 2000-05-30 | 2011-06-22 | Johnson & Johnson Research Pty Limited | METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| JP4662708B2 (ja) * | 2001-08-17 | 2011-03-30 | エクソセラ・エルエルシー | エクソゾームにタンパク質を標的化する方法および組成物 |
| NZ519371A (en) * | 2002-06-04 | 2004-11-26 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
| US7914792B2 (en) * | 2003-02-14 | 2011-03-29 | Exothera L.L.C. | Methods and compounds for raising antibodies and for screening antibody repertoires |
| EP1766053A4 (en) | 2004-06-02 | 2007-12-12 | Sourcepharm Inc | MICROVESICLES CONTAINING RNA AND METHODS |
| CN101022824A (zh) | 2004-07-01 | 2007-08-22 | 匹兹堡大学联邦系统高等教育 | 免疫抑制外体 |
| CA2504279A1 (en) | 2005-04-15 | 2006-10-15 | University Of Saskatchewan | Materials and method of modulating the immune response using t helper-antigen presenting cells |
| ES2575868T3 (es) | 2007-09-14 | 2016-07-01 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y sus usos |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES |
-
2008
- 2008-01-28 EP EP08728400A patent/EP2117305A4/en not_active Withdrawn
- 2008-01-28 CA CA002676143A patent/CA2676143A1/en not_active Abandoned
- 2008-01-28 AU AU2008207735A patent/AU2008207735B2/en not_active Ceased
- 2008-01-28 CN CN200880009056A patent/CN101641010A/zh active Pending
- 2008-01-28 BR BRPI0806436-9A patent/BRPI0806436A2/pt not_active IP Right Cessation
- 2008-01-28 JP JP2009547455A patent/JP2010516786A/ja active Pending
- 2008-01-28 US US12/524,432 patent/US8455188B2/en not_active Expired - Fee Related
- 2008-01-28 WO PCT/US2008/052205 patent/WO2008092153A2/en active Application Filing
-
2009
- 2009-07-17 ZA ZA200905005A patent/ZA200905005B/xx unknown
- 2009-07-23 IL IL200027A patent/IL200027A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516786A5 (ja) | ||
| Ziebandt et al. | Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation | |
| Altmann | A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens | |
| Nieuwland et al. | Why do cells release vesicles? | |
| NO20055347L (no) | Blandinger og framgangsmate for WT1-spesifikk immunterapi | |
| WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
| WO2010045598A3 (en) | Psma binding ligand-linker conjugates and methods for using | |
| TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
| WO2012054084A3 (en) | Antibodies | |
| Huang et al. | Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies | |
| Eckstein et al. | New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? | |
| Gámez-Chiachio et al. | Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs | |
| Xu et al. | Comparative proteomic profiling of methicillin‐susceptible and resistant Staphylococcus aureus | |
| WO2007105110A3 (en) | Ercc1 expression in predicting response for cancer chemotherapy | |
| Boyne et al. | What is the role of HLA-I on cancer derived extracellular vesicles? Defining the challenges in characterisation and potential uses of this ligandome | |
| Kurganovs et al. | A proteomic investigation of isogenic radiation resistant prostate cancer cell lines | |
| Powles | The development of immunotherapy in urothelial bladder cancer | |
| Solinas et al. | Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients | |
| Sonpavde et al. | Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed | |
| Olkhov-Mitsel et al. | Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer? | |
| Bashraheel et al. | Functional overexpression and purification of a codon optimized synthetic four superantigens in Escherichia coli: Production of superantigens with improved safety and efficacy for cancer immunotherapy (LB582) | |
| Li et al. | 657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors | |
| WO2008140580A3 (en) | Specific antibody selection by selective elution conditions | |
| Rahbari et al. | Exosomal Glypican-3 is a diagnostic and prognostic biomarker in gastric cancer | |
| Back | GBR1302-BEAT® bispecific antibody targeting CD3 and HER2 demonstrates a higher anti-tumor potential than current HER2-targeting therapies |